Les cannabinoïdes et leurs indications en antalgie chronique [Medical cannabinoids and their indications in chronic pain]
Fiche du document
15 juillet 2020
- doi: 10.53738/REVMED.2020.16.700.1363
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.700.1363
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32672015
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A8BF0E591E7C7
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Persistent pain Prescriptions Sclerosis, Multiple MS (Disease) Formularies, Medical Prescriptions Medical formularies Cannabis gigantea Gallow grass Cannabis sativa Cannabis indica PrescriptionsCiter ce document
Y. El Faleh-Kayal et al., « Les cannabinoïdes et leurs indications en antalgie chronique [Medical cannabinoids and their indications in chronic pain] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.700.1363
Métriques
Partage / Export
Résumé
Democratization of the cannabis consumption and its derivatives incite patients to ask ever more for medical cannabinoid prescriptions, especially in the context of chronic pain. Its use is only validated in certain limited cases, in particular spasticity linked to multiple sclerosis and refractory epilepsies. All other prescriptions require a special request to the OFSP. Moreover, cannabinoid intake may produce several dose-dependent side effects that require a close monitoring with a slow and gradual initiation of its dosage. In the absence of clear medical evidence, many other mechanisms of action need to be investigated with ongoing and future studies to clarify their indication.